Brentuximab vedotin for relapse or progression therapy after allogeneic hematopoietic stem cell transplantation in relapsed / refractory classic Hodgkin lymphoma

被引：0
|
作者：
Mikhailova, N. [1 ]
Popova, M. [1 ]
Kondakova, E. [1 ]
Ivanova, M. [1 ]
Borzenkova, E. [1 ]
Alaynskiy, A. [1 ]
Bondarenko, S. [1 ]
Afanasyev, B. [1 ]
Babenko, E. [1 ]
机构：
[1] First St Petersburg Pavlov State Med Univ, St Petersburg, Russia
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P728
引用
收藏
页码：S503 / S503
页数：1
相关论文
共 50 条
  • [41] The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma
    Kako, Shinichi
    Izutsu, Koji
    Kato, Koji
    Kim, Sung-Won
    Mori, Takehiko
    Fukuda, Takahiro
    Kobayashi, Naoki
    Taji, Hirofumi
    Hashimoto, Hisako
    Kondo, Tadakazu
    Sakamaki, Hisashi
    Morishima, Yasuo
    Kato, Koji
    Suzuki, Ritsuro
    Suzumiya, Junji
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (02) : 132 - 138
  • [42] Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma
    Damlaj, Moussab
    Abuelgasim, Khadega A.
    Alhejazi, Ayman
    Alahmari, Bader
    Alaskar, Ahmed
    Alzahrani, Mohsen
    BONE MARROW TRANSPLANTATION, 2020, 55 (12) : 2322 - 2325
  • [43] Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma
    Moussab Damlaj
    Khadega A. Abuelgasim
    Ayman Alhejazi
    Bader Alahmari
    Ahmed Alaskar
    Mohsen Alzahrani
    Bone Marrow Transplantation, 2020, 55 : 2322 - 2325
  • [44] Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Illidge, Tim
    Bouabdallah, Reda
    Chen, Robert
    Gopal, Ajay K.
    Moskowitz, Craig H.
    Ramchandren, Radhakrishnan
    Shustov, Andrei R.
    Tilly, Herve
    Trippett, Tanya M.
    Gibb, Adam
    Grove, Laurie E.
    Advani, Ranjana
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 703 - 710
  • [45] Functional Imaging Predicts Progression-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Relapsed/Refractory Hodgkin Lymphoma
    Cho, Christina
    Eaton, Anne
    Barker, Juliet N.
    Castro-Malaspina, Hugo
    Devlin, Sean M.
    Moskowitz, Alison
    Sauter, Craig S.
    Moskowitz, Craig H.
    Perales, Miguel-Angel
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S218 - S219
  • [46] Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma
    Fernandez, Karen S.
    Mavers, Melissa
    Marks, Lianna J.
    Agarwal, Rajni
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (02) : E191 - E194
  • [47] Low-Dose Nivolumab Plus Brentuximab Vedotin As a Bridge to Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma
    Colunga-Pedraza, Panelperla R. R.
    Ulises Coronado-Alejandro, Edgar
    De La Garza, Fernando
    Gomez Gomez, Eliezer Tomas
    Gomez-De Leon, Andres
    Colunga Pedraza, Julia Esther
    Homero Gutierrez-Aguirre, Cesar
    Cantu Rodriguez, Olga Graciela
    Gomez-Almaguer, David
    BLOOD, 2021, 138
  • [48] Economic Burden in US Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin or Chemotherapy after Failure of Autologous Hematopoietic Cell Transplantation
    Chen, Clara
    Johnston, Karissa
    Szabo, Shelagh
    Connors, Joseph M.
    Yasenchak, Christopher A.
    BLOOD, 2017, 130
  • [49] Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma
    Chen, Robert
    Palmer, Joycelynne M.
    Tsai, Ni-Chun
    Thomas, Sandra H.
    Siddiqi, Tanya
    Popplewell, Leslie
    Faro, Len
    Nademanee, Auayporn
    Forman, Stephen J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (11) : 1864 - 1868
  • [50] Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy
    LaCasce, Ann
    Bociek, R. Gregory
    Matous, Jeffrey
    Sawas, Ahmed
    Caimi, Paolo
    Ansell, Stephen M.
    Islas-Ohlmayer, Miguel
    Cheung, Eric
    Agura, Edward
    Behler, Caroline
    Crosswell, Howland
    Vose, Julie M.
    Josephson, Neil
    Advani, Ranjana
    BLOOD, 2014, 124 (21)
12345